Maddi Hebebrand, MC, Associate Editor

Jacob Thyssen, PhD, discusses tralokinumab's promising results for hand eczema, highlighting its potential to transform treatment options for patients.

We want to know: Will you be attending the conference in Seattle this week?

Matthew Zirwas, MD, discusses the complexities of safety analysis in psoriasis clinical trials, advocating for exposure-adjusted incidence rates to enhance risk communication.

Social media spreads significant retinol misinformation, risking adolescent skin health. Experts call for improved digital education and accurate content creation.

Replimune faces FDA challenges for RP1's approval in advanced melanoma, highlighting complexities in cancer drug development and regulatory scrutiny.

Bristol Myers Squibb's deucravacitinib gains global regulatory acceptance for treating active psoriatic arthritis, promising a new oral treatment option.

The 2025 Fall Clinical Dermatology Conference energized PAs and NPs with innovative strategies, addressing burnout, digital branding, and personalized medicine.

A retrospective case series found that apremilast induced complete remission in 6 men with treatment-resistant genital psoriasis.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The dermatology community mourns the loss of Dr. Robert Sidbury, a visionary leader in pediatric dermatology, whose impact and mentorship resonate deeply.

Jacki Kment, PA-C, MPAS, DFAAPA, shares how she built a successful direct pay dermatology practice to prioritize patient care and professional balance.

Abrocitinib significantly improves lesion severity and pruritus in moderate to severe AD, offering a promising treatment option for patients.

With longer visits and flat-rate pricing, Kment’s practice provides personalized dermatologic care to both insured and uninsured patients.

Explore how genetic factors influence acute and chronic urticaria, revealing potential for personalized treatment strategies.

A recent study reveals distinct patterns of nonsegmental vitiligo lesions on hands.

New insights reveal shared and allergen-specific immune responses in allergic contact dermatitis.

Turn Therapeutics initiates a groundbreaking clinical trial for GX-03, the first topical IL-36 inhibitor targeting moderate to severe eczema.

A national Delphi survey reveals critical insights into CHE management in France, highlighting the need for standardized assessment and guidelines.

Melanoma survivors share their diagnoses and advocate for early detection, routine skin exams, and public education to save lives.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

OJM Group’s David Mandell, JD, MBA, shares financial planning strategies for physicians facing new tax laws and market volatility.

A systematic review reveals critical diagnostic gaps in hair loss treatment for patients with skin of color, urging improved training and protocols in dermatology.

A pilot study evaluates tildrakizumab's safety and potential in treating stable nonsegmental vitiligo, highlighting the need for further research on IL-23 inhibitors.

FDA enhances transparency by publishing over 200 Complete Response Letters, offering insights into drug approval processes and common deficiencies.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

Delgocitinib cream offers a safe, effective treatment for chronic hand eczema with minimal systemic absorption, ensuring no significant immunosuppressive effects.